Introduction On the basis of the findings of the phase 3 PACIFIC trial (NCT02125461),
durvalumab is standard of care for patients with stage III, unresectable NSCLC and no disease …

Many efficacious cancer treatments cause significant cardiac morbidity, yet biomarkers or
functional indices of early damage, which would allow monitoring and intervention, are lacking. …

Discussion TEN is a rare but life-threatening dermatologic emergency, resulting from CD8+
T lymphocytes inducing apoptosis of epithelial keratinocytes. 5 An erythematous macular …

Background In the ph 3, placebo-controlled PACIFIC trial, durvalumab (durva) after concurrent
CRT (cCRT) significantly improved survival in pts with Stage III, unresectable NSCLC, …

Background Pembrolizumab is licensed for the treatment of pre-treated and PD-L1 positive
non-small cell lung cancer (NSCLC), but response is heterogeneous. In this context, the …

PURPOSE The Christie NHS Foundation Trust launched their electronic patient-reported
outcome measures (ePROMs) service in January 2019 in the routine clinical setting. The lung …

Methods A retrospective review of all lung cancer patients with a multidisciplinary team
outcome of BSC from 01 June 2018 to 01 June 2019 was performed. Patients were categorised …

High-dose interleukin 2 (HD-IL2) is one of the therapeutic options for patients with metastatic
renal cell carcinoma. In well-selected patients with favorable clinical and pathologic features…

Methods A retrospective cohort study investigating patients with advanced NSCLC with
METexon 14 skipping mutations–detected on either tissue or liquid biopsy. Primary outcome …

Methods We retrospectively reviewed consecutive pts with aNSCLC with PD-L1> 50% who
were treated with first-line pembrolizumab (n= 288) or atezolizumab (n= 61) at The Christie …